The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

This repository contains code for efficiently fitting parametric SMPL/SMPL+H/SMPL-X human body models to nonparametric 3D vertex and joint locations. The input needs to be in correspondence with the ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...